Applied BioCode operates in the biotechnology sector, specializing in digital multiplexing molecular platforms designed for molecular and protein testing. The company's core technology revolves around Barcode Magnetic Beads (BMBs), which are micrometer-scaled and significantly smaller than conventional barcodes. These BMBs are biocompatible and can be used to barcode various biomarkers, enabling comprehensive molecular tests. Applied BioCode serves a diverse range of clients, including clinical laboratories, research institutions, and healthcare providers, offering solutions for molecular diagnostics, gene expression, and biomarker discovery.

The company operates primarily in the clinical diagnostics market, providing assays for respiratory pathogens, gastrointestinal pathogens, and other infectious diseases. Applied BioCode's business model is centered on the sale of its proprietary testing platforms and associated consumables, such as assay kits and BMBs. Revenue is generated through the sale of these products and services, as well as through partnerships and collaborations with other entities in the healthcare and life sciences sectors.

Applied BioCode has received FDA 510(k) clearance for its Respiratory Pathogen Panel and Emergency Use Authorization for its SARS-CoV-2 assay, underscoring the reliability and regulatory compliance of its products. The company's offerings are designed to provide high sensitivity and seamless automation for PCR, hybridization, and detection processes, making them suitable for high-volume testing environments.

Keywords: digital multiplexing, molecular testing, protein biomarkers, Barcode Magnetic Beads, clinical diagnostics, FDA clearance, SARS-CoV-2 assay, gene expression, biomarker discovery, high sensitivity.